OCT 09, 2019 7:30 AM PDT

Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF
    Biography
      Ernesto Diaz-Flores, PhD, is an Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF. He is an experienced biochemist with a focus on identifying novel therapeutics for high-risk childhood leukemia. Dr. Diaz-Flores obtained his BsC in Biochemistry at the Universidad Complutense (Madrid) and his PhD in molecular biology for his studies of lymphocyte activation at the Universidad Autonoma (Madrid). He came to UCSF for his postdoctoral studies first under the supervision of Dr Kevin Shannon, studying murine models of Kras leukemia and then pursuing a second postdoctoral fellowship in Dr. Mignon Loh's laboratory. Dr Diaz-Flores specializes in identifying novel therapies for children with hypodiploid leukemia. His work combines the study of dysregulated signaling networks, transcriptomics analysis and drug assays. He further validates drugs with therapeutic potential running in vivo preclinical trials using patient derived xenografted models. His latest work has informed a clinical trial for patients with high-risk leukemia

    Abstract

    Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading causes of childhood cancer mortality. This is largely due to specific leukemia subtypes being resistant to treatment. One of these subtypes is hypodiploid B cell leukemia characterized by multiple chromosomal losses. For these patients, treatment options remain limited, and their prognosis is dim.

    Learning Objectives:

    1. How to integrate genomics and proteomics profiling with drug screens to identify potential therapeutic targets

    2. How to move from in vitro to in vivo preclinical studies to inform new clinical trials.

    3. The audience will learn about hypodiploidy: from cytogenetics to prognosis to drug response in the context of leukemia.

     


    Show Resources
    You May Also Like
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    Loading Comments...
    Show Resources
    Attendees